South Korean biosimilar maker Celltrion expects to surpass ₩1 trillion ($694 million) in annual operating profit for the first time in its history after posting what would be record quarterly earnings in the final three months of 2025.
The company forecast fourth-quarter revenue of ₩1.28 trillion ($889 million) and operating profit of ₩472.2 billion ($328 million), representing year-over-year increases of 20.7% and 140.4%, respectively. The projected operating margin of 36.8% would mark a substantial improvement from prior quarters.
For the full year, Celltrion anticipates revenue of ₩4.12 trillion ($2.86 billion) and operating profit of ₩1.17 trillion ($813 million), up 15.7% and 136.9% from 2024.
The results, which remain subject to auditor review, reflect expanding sales of newer biosimilars including Remsima SC (sold as Zymfentra in the U.S.), Yuflyma, Vegzelma, and Steqeyma. These products are expected to contribute more than 60% of quarterly revenue, signaling a successful transition from legacy treatments.
Still, the figures fall short of earlier analyst projections for ₩5 trillion in annual sales, partly due to delays in certain product launches stemming from patent settlements and supply chain constraints. Celltrion indicated these products should gain market share from 2026 onward, though execution remains a key variable for investors watching whether the company can sustain its margin expansion.
